Loading stock…

Biogen Inc. (BIIB) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Biogen Inc.

BIIBMarket cap $33BPrice $222.9

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops treatments for neurological diseases like Alzheimer's and ALS, betting big on the brain when most biotechs avoid it. One of the few companies with an approved drug targeting Alzheimer's root cause, not just symptoms.

In Bastion Portfolios?

52W Return+56%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-1%3

Revenue Forecast

Rev CAGR (1y)+6%4

Rev CAGR (3y)+4%3

Rev CAGR (5y)+2%2

Earnings Forecast

EPS Growth Y+1+42%9

EPS Growth Y+2+31%9

EPS Growth Y+3+13%7

Quality

Margins

EBIT Margin25%8

Net Income Margin8%5

Free Cash Flow Margin27%9

Debt

Net Debt/EBITDA2.04

Efficiency

ROE5%3

ROA3%4

Earnings Stability44

GEAR+AVERAGE44

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)175

P/E Ratio (Forward 3y)126

P/BV1.77

EV Multiples

EV/EBITDA Fwd144

EV/EBIT Fwd165

Yield

Free Cash Flow Yield8.2%8

Dividend Yieldna–

Momentum

Short term

1 month return+1%8

3 month return+8%8

YTD return+27%8

Mid term

Price vs 52wHigh97%10

1 year return+46%9

Long term

3 year return-15%2

5 year return-23%2

Risk Shield

Price Risk

Beta0.58

Volatility33%6

Free Cash Flow

Free Cash Flow Margin27%9

Free Cash Flow Yield8.2%8

Quality

ROCE9%5

Earnings Stability44

Net Debt/EBITDA2.04

02Growth

Is it actually growing, and how fast?

BIIBBiogen

Revenue FY25$9.9B

GROWTH RATING↗

WEAK25 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-1%3

Revenue, next 1Y+6%4

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+2%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+42%9

EPS growth, FY27E+31%9

EPS growth, FY28E+13%7

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 31%/yr vs revenue 4%/yr), so margins should widen.

WATCH

After shrinking over the last 3 years, revenue is set to grow 4%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 75% of companies worldwide.

Revenue fell 0.9%/yr over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 2%/yr, behind 80% of companies worldwide.2/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG70 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return+8%8

YTD return+27%8

MID & LONG-TERM▾SCORE

% of 52-week high97%10

1-year return+46%9

3-year return-15%2

5-year return-23%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 46% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+1%), over three months (+8%) and so far this year (+27%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-15% over three years and -23% over five), behind 80% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Biogen Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

BIIBBiogen

Revenue FY25$9.9B

GROWTH RATING↗

WEAK25 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-1%3

Revenue, next 1Y+6%4

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+2%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+42%9

EPS growth, FY27E+31%9

EPS growth, FY28E+13%7

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 31%/yr vs revenue 4%/yr), so margins should widen.

WATCH

After shrinking over the last 3 years, revenue is set to grow 4%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 75% of companies worldwide.

Revenue fell 0.9%/yr over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 2%/yr, behind 80% of companies worldwide.2/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG70 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return+8%8

YTD return+27%8

MID & LONG-TERM▾SCORE

% of 52-week high97%10

1-year return+46%9

3-year return-15%2

5-year return-23%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 46% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+1%), over three months (+8%) and so far this year (+27%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-15% over three years and -23% over five), behind 80% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Biogen Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community